Chengdu Hongji Biotechnology Co., Ltd. announced that it will receive CNY 159,736,344 in an equity round of funding on July 12, 2023. The transaction will include participation from returning investors Chengdu Kanghong Pharmaceutical Group Co., Ltd for 86.95%, Chengdu Kangji Enterprise Management Consulting Partnership (Limited Partnership) for 7.19% stake, Chengdu Kangyin Enterprise Management Consulting Partnership (Limited Partnership) for 3.31% stake and Chengdu Kangzhi Technology Consulting Partnership (Limited Partnership) for 2.55% stake in the company. The transaction was approved by the board of the directors of Chengdu Kanghong Pharmaceuticals Group Co., Ltd at its twentieth meeting of the seventh board of directors and seventeenth meeting of the seventh board of supervisors The transaction still needs to be approved by the company's shareholders meeting.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
22.35 CNY | +0.13% | -1.15% | +21.20% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+21.20% | 2.84B | |
+40.73% | 739B | |
+31.44% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.25% | 240B | |
+9.53% | 210B | |
-5.11% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- 002773 Stock
- News Chengdu Kanghong Pharmaceutical Group Co., Ltd
- Chengdu Hongji Biotechnology Co., Ltd. announced that it expects to receive CNY 159.736344 million in funding from Chengdu Kanghong Pharmaceutical Group Co., Ltd, Chengdu Kangji Enterprise Management Consulting Partnership (Limited Partnership), Chengdu Kangyin Enterprise Management Consulting Partnership (Limited Partnership), Chengdu Kangzhi Technology Consulting Partnership (Limited Partnership)